David Feifel

Professor Emeritus of Psychiatry at the University of California, San Diego; President of Kadima Neuropsychiatry Institute

Data updated

Papers

6 publications

Trials

0 clinical trials

Links

Website

Research Footprint

David Feifel appears in 6 tracked papers (2017–2026), most studied alongside Psilocybin and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).

Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).

Frequent co-authors: Guy Goodwin, Ekaterina Malievskaia and Lindsey Marwood.

Background & Research

David Feifel earned B.Sc., M.A., M.D., and Ph.D. degrees in neurobiology from the University of Toronto and completed his psychiatry residency at UC San Diego. He became a professor in the UCSD Department of Psychiatry, where he directed the Neuropsychiatry and Behavioral Medicine Program and founded the Center for Advanced Treatment of Mood and Anxiety Disorders. He later founded Kadima Neuropsychiatry Institute in La Jolla and has remained active in ketamine, TMS, and psychedelic-treatment research.

Key Impact

David Feifel is a prominent psychiatrist and neuropsychiatrist who helped pioneer ketamine-based treatment programs and has coauthored clinical psychedelic research on psilocybin for treatment-resistant depression.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

29 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinKetamine

Topics

Depressive DisordersTreatment-Resistant Depression (TRD)Major Depressive Disorder (MDD)SuicidalitySafety & Risk ManagementAnxiety DisordersAdolescentsOlder AdultsBipolar DisorderImplementation & Service DeliveryHealthy VolunteersHeadache Disorders (Cluster & Migraine)Chronic PainNeuroimaging & Brain Measures

Top Collaborators

Affiliations

Institutions, companies, and organisations David Feifel is associated with.

National Network of Depression Centers

Non-Profit

The National Network of Depression Centers is a U.S.-based nonprofit consortium of academic medical centers and mental health programs focused on depression, bipolar disorder, and related mood disorders. It operates nationally across member sites in the United States and is centered in Ann Arbor, Michigan. Its core activities include collaborative research, clinical education, outreach, and network-based improvement of evidence-based care. In the psychedelic-adjacent space, NNDC appears primarily as a mood-disorders research and clinical collaboration network rather than a dedicated psychedelic policy group. Its ketamine task group was created to share information and experience as ketamine and esketamine clinics expanded across the network, and NNDC has also reported on the BIO-K biomarker study of ketamine for major depression. This makes it relevant to researchers, clinicians, and funders working on interventional psychiatry, treatment-resistant depression, and evidence-building around regulated access pathways.

View stakeholder →